ClinicalTrials.gg
CompletedNCT05065190Updated May 20, 2025Results posted

A Study to Test How Well a Medicine Called Nintedanib Helps People in China With Progressive Lung Fibrosis

A Phase 3 interventional study of Nintedanib and Placebo in Lung Diseases, Interstitial, sponsored by Boehringer Ingelheim. Completed at 16 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-05-20.

Sponsored by Boehringer Ingelheim · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
81
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 11 studies testing nintedanib in Lung Diseases, Interstitial — 1 open to participants now, 1 under way, 1 of them phase 3. nintedanib · Lung Diseases, Interstitial.

Enrollment
6th of 11
81 · median 81
Started
2021
with 2 others
Phase 3
8 of 11
1 open now
Registered
7th of 11
by date
Lead sponsor
6 of 11
Boehringer Ingelheim

Among the 11 studies testing nintedanib in Lung Diseases, Interstitial, this one is the 6th largest by enrollment, is one of 3 that started in 2021, is one of 8 in phase 3, and was the 7th registered.

Lung Diseases, Interstitial

682 studies on the registry are indexed under Lung Diseases, Interstitial; 245 are open to participants now.

Browse Lung Diseases, Interstitial studies →

Open to participants now

1 of the 11 studies testing nintedanib in Lung Diseases, Interstitial is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About nintedanib

nintedanib: first FDA approval 2014 (OFEV), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 172 Lung Diseases, Interstitial studies recruiting now, 108 (63%) set no upper age limit and 25 (15%) stop at 75 or younger; 13 take children under 18; 21 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies testing nintedanib in Lung Diseases, Interstitial, or all of them as a file.
02

Study summary

This study in China is open to people with progressive lung fibrosis (chronic fibrosing ILDs with progressive phenotype) who are at least 18 years old. The purpose of this study is to find out whether a medicine called nintedanib helps people with progressive lung fibrosis.

Participants are put into 2 groups randomly, which means by chance. 1 group gets nintedanib as capsules twice a day. The other group gets placebo as capsules twice a day. Placebo capsules look like nintedanib capsules but do not contain any medicine.

Participants are in the study for about 1 year. During this time, they visit the study site about 10 times. At some visits, participants perform a lung function test. The doctors check whether study treatment can slow down the loss of lung function. The doctors also regularly check participants' health and take note of any unwanted effects.

03

Conditions studied

  • Lung Diseases, Interstitial
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Written consistent with International Council on Harmonisation-Good Clinical Practice (ICH-GCP) and local laws signed prior to entry into the study (and prior to any study procedure including shipment of High-Resolution Computed Tomography (HRCT) to reviewer.
  • Male or female patients aged ≥ 18 years at Visit 1.
  • Patients with physician diagnosed Interstitial Lung Disease (ILD) who fulfil at least one of the following criteria for Progressive Phenotype within 24 months of screening visit (Visit 1) despite treatment with unapproved medications used in clinical practice to treat ILD, as assessed by the investigator:

    • decline in Forced Vital Capacity (FVC) % predicted based on a relative decline of ≥10%
    • Marginal decline in FVC % predicted based on a relative decline of ≥5-\<10% combined with worsening of respiratory symptoms
    • Marginal decline in FVC % predicted based on a relative decline of ≥5-\<10% combined with increasing extent of fibrotic changes on chest imaging
    • Worsening of respiratory symptoms as well as increasing extent of fibrotic changes on chest imaging [Note: Changes attributable to comorbidities e.g. infection, heart failure must be excluded. Unapproved medications used in the clinical practice to treat ILD include but are not limited to , azathioprine, mycophenolate mofetil (MMF), n-Acetylcysteine (NAC), rituximab, cyclophosphamide, cyclosporine, tacrolimus].
  • Fibrosing lung disease on HRCT, defined as reticular abnormality with traction bronchiectasis with or without honeycombing, with disease extent of >10%, performed within 12 months of Visit 1 as confirmed by central readers.
  • For patients with underlying Connective Tissue Disease (CTD): stable CTD as defined by no initiation of new therapy or withdrawal of therapy for CTD within 6 weeks prior to Visit 1.
  • FVC ≥ 45% predicted at Visit 2.

Exclusion criteria

Exclusion Criteria:

  • (AST) and / or Alanine Aminotransferase (ALT) > 1.5 x Upper Level of Normal () at Visit 1
  • > 1.5 x ULN at Visit 1
  • \<30 milliliter (mL)/minute (min) calculated by Cockcroft-Gault formula at Visit 1.

[Note: Laboratory parameters from Visit 1 have to satisfy the laboratory threshold values as shown above. Visit 2 laboratory results will be available only after randomization. In case at Visit 2 the results do no longer satisfy the entry criteria, the Investigator has to decide whether it is justified that the patient remains on study drug. The justification for decision needs to be documented. Laboratory parameters that are found to be abnormal at Visit 1 are allowed to be re-tested (once) if it is thought to be a measurement error (i.e. there was no abnormal result of this test in the recent history of the patient and there is no related clinical sign) or the result of a temporary and reversible medical condition, once that condition is resolved].

  • Patients with underlying chronic liver disease ( A, B or C hepatic impairment).
  • Previous treatment with nintedanib or pirfenidone.
  • Other therapy received within 1 month or 6 half-lives (whichever was greater) prior to screening visit (Visit 1).
  • Use of any of the following medications for the treatment of Interstitial Lung Disease (ILD): azathioprine (AZA), cyclosporine, Mycophenolate Mofetil (MMF), tacrolimus, oral (OCS) >20mg/day and the combination of OCS+AZA+ n-Acetylcysteine (NAC) within 4 weeks of Visit 2, cyclophosphamide within 8 weeks of Visit 2, rituximab within 6 months of Visit 2.

Note: Patients whose Regulatory Authority (RA)/Connective Tissue Disease (CTD) is managed by these medications should not be considered for participation in the current study unless change in RA/CTD medication is medically indicated.

Further exclusion criteria apply.

Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
81 participants (actual)

Study arms

  • Experimental
    150 mg Nintedanib

    A soft gelatin capsule of 150 mg Nintedanib was administered orally twice daily (bid) in Chinese patients with chronic fibrosing ILD with progressive phenotype with over 52 weeks. Dose could be reduced to 100 mg bid to manage adverse events.

    Drug: Nintedanib

  • Placebo comparator
    Placebo

    A soft gelatin capsule of placebo matching in size, weight, colour and shape to 150 milligram (mg) or 100 mg soft gelatin capsule of Nintedanib, was administered orally twice daily (bid) in Chinese patients with chronic fibrosing Interstitial Lung Disease (ILD) with progressive phenotype with over 52 weeks.

    Drug: Placebo

Interventions

  • Soft gelatin capsule

  • DrugPlacebo

    Soft gelatin capsule

06

What researchers measure

Primary outcomes

  1. Annual Rate of Decline in Forced Vital Capacity (FVC) Over 52 Weeks Expressed in Milliliter (mL)

    Annual rate of decline in FVC over 52 weeks expressed in milliliter (mL). The main analysis used a restricted maximum likelihood (REML)-based approach with a random slope and intercept model. The analysis included the fixed, categorical effects of treatment, high resolution computed tomography (HRCT) pattern at baseline, fixed continuous effects of time and baseline FVC as well as the treatment-by-time and baseline-by-time interactions. Random effects were included for the patient response for both time and intercept. For patients who prematurely discontinued study treatment, data collected at follow-up visit and visits after treatment discontinuation was included in the analysis.

    Time frame: From baseline up to Week 52.

07

Results

Posted May 20, 2025

Participant flow

A double blind, randomized, placebo-controlled trial to generate additional data on the efficacy of 150 mg bid nintedanib in Chinese patients with Chronic Fibrosing Interstitial Lung Disease (ILD) with a progressive phenotype compared with placebo over 52 weeks.

Participant flow — Overall Study
MilestonePlacebo150 mg Nintedanib
Started2754
Completed2032
Not completed722
Withdrew: Other than listed212
Withdrew: Lack of efficacy40
Withdrew: Adverse event110

Outcome measures

PrimaryAnnual Rate of Decline in Forced Vital Capacity (FVC) Over 52 Weeks Expressed in Milliliter (mL)

Annual rate of decline in FVC over 52 weeks expressed in milliliter (mL). The main analysis used a restricted maximum likelihood (REML)-based approach with a random slope and intercept model. The analysis included the fixed, categorical effects of treatment, high resolution computed tomography (HRCT) pattern at baseline, fixed continuous effects of time and baseline FVC as well as the treatment-by-time and baseline-by-time interactions. Random effects were included for the patient response for both time and intercept. For patients who prematurely discontinued study treatment, data collected at follow-up visit and visits after treatment discontinuation was included in the analysis.

Time frame:
From baseline up to Week 52.
Reported as:
Number · Milliliter/year
Annual Rate of Decline in Forced Vital Capacity (FVC) Over 52 Weeks Expressed in Milliliter (mL)
Milliliter/yearPlacebo150 mg Nintedanib
Annual Rate of Decline in Forced Vital Capacity (FVC) Over 52 Weeks Expressed in Milliliter (mL)-191.89 (-313.15 to -70.63)-85.32 (-176.40 to 5.76)
Statistical analysis
  • Placebo vs 150 mg Nintedanib · Adjusted difference: 106.57 · 95% CI -47.13 to 260.28Adjusted difference between treatment groups was based on a random slope and intercept model with fixed effects for treatment, HRCT pattern, and baseline FVC \[mL\], and including treatment-by-time and baseline-by-time interactions.

Adverse events

Collected over All-cause mortality, serious and other adverse events: From first drug intake until end of trial visit, plus 7 days of residual effect period, up to 53 weeks.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo3/27 (11.1%)12/27 (44.4%)23/27 (85.2%)
150 mg Nintedanib6/54 (11.1%)20/54 (37%)51/54 (94.4%)
Most frequent serious events
Showing 10 of 35
Most frequent serious events
EventPlacebo150 mg Nintedanib
PneumoniaInfections and infestations4/275/54
Interstitial lung diseaseRespiratory, thoracic and mediastinal disorders3/270/54
Upper respiratory tract infectionInfections and infestations2/270/54
Respiratory failureRespiratory, thoracic and mediastinal disorders2/272/54
Cardiac failureCardiac disorders1/271/54
Chest painGeneral disorders1/270/54
COVID-19 pneumoniaInfections and infestations1/272/54
Lung neoplasm malignantNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/270/54
AsthmaRespiratory, thoracic and mediastinal disorders1/270/54
Lung disorderRespiratory, thoracic and mediastinal disorders1/270/54
Most frequent other events
Showing 10 of 36
Most frequent other events
EventPlacebo150 mg Nintedanib
DiarrhoeaGastrointestinal disorders4/2719/54
COVID-19Infections and infestations7/2714/54
Hepatic function abnormalHepatobiliary disorders2/2712/54
Alanine aminotransferase increasedInvestigations1/2710/54
Gamma-glutamyltransferase increasedInvestigations1/2710/54
CoughRespiratory, thoracic and mediastinal disorders5/276/54
Aspartate aminotransferase increasedInvestigations2/278/54
Interstitial lung diseaseRespiratory, thoracic and mediastinal disorders4/275/54
Abdominal discomfortGastrointestinal disorders1/277/54
VomitingGastrointestinal disorders1/277/54

Baseline characteristics

Treated Set (TS): All patients who were randomized to a treatment group and received at least one dose of study medication.

Age, Continuous
Age, Continuous(Years)Placebo150 mg NintedanibTotal
Mean65.8 ± 8.463.8 ± 8.464.5 ± 8.4
Sex: Female, Male
Sex: Female, Male(Participants)Placebo150 mg NintedanibTotal
Female162844
Male112637
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Placebo150 mg NintedanibTotal
Hispanic or Latino000
Not Hispanic or Latino275481
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Placebo150 mg NintedanibTotal
American Indian or Alaska Native000
Asian275481
Native Hawaiian or Other Pacific Islander000
Black or African American000
White000
More than one race000
Unknown or Not Reported000
08

Study locations

16 sites
  • China-Japan Friendship Hospital
    Beijing, 100029, China
  • The Second Hospital of Jilin University
    Changchun, 130041, China
  • Xiangya Hospital, Central South University
    Changsha, 410008, China
  • West China Hospital
    Chengdu, 610042, China
  • First Affiliated Hospital of Guangzhou Medical University
    Guangzhou, 510120, China
  • Hangzhou First People's Hospital
    Hangzhou, 310006, China
  • The Second Affiliated Hospital Zhejiang University School of Medicine
    Hangzhou, 310009, China
  • Zhejiang Hospital
    Hangzhou, 310013, China
  • Nanjing Drum Tower Hospital
    Nanjing, 210008, China
  • Shanghai Chest Hospital
    Shanghai, 200030, China
  • Huashan Hospital, Fudan University
    Shanghai, 200040, China
  • Shanghai Pulmonary Hospital
    Shanghai, 200433, China
  • Tianjin Medical University General Hospital
    Tianjin, 30052, China
  • The First Affiliated Hospital of Wenzhou Med College
    Wenzhou, 325000, China
  • Tongji Hospital Affiliated Tongji Medical College Huazhong University of S & T
    Wuhan, 430030, China
  • General Hospital of Ningxia Medical University
    Yinchuan, 750004, China
09

References and documents

Related links

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — After the study is completed and the primary manuscript is accepted for publishing, researchers can use this following link https://www.mystudywindow.com/msw/datasharing to request access to the clinical study documents regarding this study, and upon a signed "Document Sharing Agreement". Also, Researchers can use the following link https://www.mystudywindow.com/msw/datasharing to find information in order to request access to the clinical study data, for this and other listed studies, after the submission of a research proposal and according to the terms outlined in the website. The data shared are the raw clinical study data sets.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: After all regulatory activities are completed in the US and EU for the product and indication, and after the primary manuscript has been accepted for publication.

Access criteria: For study documents - upon signing of a 'Document Sharing Agreement'. For study data - 1. after the submission and approval of the research proposal (checks will be performed by both the independent review panel and the sponsor, including checking that the planned analysis does not compete with sponsor's publication plan); 2. and upon signing of a 'Data Sharing Agreement'.

Data sharing details ↗ · www.mystudywindow.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2021 to primary completion in Apr 2024, 29 months.

Results were first posted in May 2025, 1 year after primary completion.

Of 36 phase 3 interventional studies under Lung Diseases, Interstitial, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 61. This study's 29 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 30, 2021
First posted
Oct 1, 2021
StartActual
Nov 25, 2021
Primary completionActual
Apr 30, 2024
CompletionActual
May 7, 2024
Results first posted
May 20, 2025
Last update
May 20, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 20, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05065190
Responsible party
Sponsor
First posted
Oct 1, 2021
Start date
Nov 25, 2021
Primary completion
Apr 30, 2024
Completion
May 7, 2024
Results posted
May 20, 2025
Last update
May 20, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nintedanib

Start the discussion